Most researchers trying to source CJC-1295 in Pact quickly find that local retail options are nearly impossible to find. The practical advantage of this online-only market is that serious vendors differentiate entirely through their analytical documentation, giving researchers access to better quality signals than any physical store could provide. What genuinely separates top CJC-1295 vendors is comprehensive lot-matched testing data: HPLC for purity, mass spec for molecular identity verification, and endotoxin testing for contamination assurance. This guide walks Pact researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
CJC-1295 Mechanisms Explained
CJC-1295 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Pact studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
CJC-1295 Purchasing Guide
The most reliable path to quality CJC-1295 is engaging research communities before vendor sites — peptide forums maintain informal vendor reputation databases that are more accurate than commercial vendor claims. The HPLC analytical chromatogram is the most important document in the COA: it should show a clear dominant peak representing CJC-1295, with negligible secondary peaks representing impurities — purity should be at or above 98%. For Pact researchers evaluating new suppliers: a test quantity before committing to research volumes before scaling up your order is standard practice in the community. Price is an ineffective primary criterion for CJC-1295 quality — research-grade synthesis and testing has genuine production costs that cannot be cut without consequences, so unusually low prices consistently indicate quality reductions.
Order CJC-1295 — ships to Pact
COA-verified · International tracking · Research grade
All use of CJC-1295 in Pact or anywhere must be research use only — this compound is not approved for clinical human use, and all handling should adhere to research compound handling standards. Lyophilised CJC-1295 should be placed in the freezer at −20°C straight away; avoid repeatedly thawing and refreezing reconstituted peptide by preparing small aliquots before storage. Verify the endotoxin level in your CJC-1295 batch COA before any protocol involving administration — look for results stated as EU/mg and compare against acceptable research limits for your application. The research literature on CJC-1295 should be reviewed carefully before designing any protocol — study approaches, dose levels, and measured endpoints vary significantly and conclusions do not uniformly extrapolate.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
